Drug Type Small molecule drug |
Synonyms Danirixin (USAN/INN), DNX, GSK-1325756 + [3] |
Target |
Action antagonists |
Mechanism CXCR2 antagonists(C-X-C motif chemokine receptor 2 antagonists) |
Active Indication- |
Inactive Indication |
Molecular FormulaC19H21ClFN3O4S |
InChIKeyNGYNBSHYFOFVLS-LBPRGKRZSA-N |
CAS Registry954126-98-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Influenza, Human | Phase 2 | United States | 01 Jun 2015 | |
Influenza, Human | Phase 2 | Australia | 01 Jun 2015 | |
Influenza, Human | Phase 2 | South Africa | 01 Jun 2015 | |
Pulmonary Disease, Chronic Obstructive | Phase 2 | United States | 13 Feb 2014 | |
Pulmonary Disease, Chronic Obstructive | Phase 2 | Germany | 13 Feb 2014 | |
Respiratory Syncytial Virus Infections | Phase 1 | United States | 13 Jan 2014 | |
Malnutrition | Phase 1 | United States | 14 Apr 2010 |
Phase 2 | 614 | ypradepdkt(mwuouwrgcl) = There were no improvements in E-RS:COPD, CAT or SGRQ-C scores in participants treated with any dose of danirixin compared to placebo. kcmebwdedb (rnfesudmmx ) View more | Negative | 12 Jun 2020 | |||
placebo | |||||||
Phase 2 | 54 | placebo (Placebo) | jlcistdvid(ooglolhczo) = npnixzmzyu fnbqthmuox (jzykdaakdu, 110.75) View more | - | 05 Feb 2020 | ||
(DNX HBr 35 mg) | jlcistdvid(ooglolhczo) = yaknrydjlh fnbqthmuox (jzykdaakdu, 115.01) View more | ||||||
Phase 2 | 614 | Standard of care (Placebo) | alnpbngaln(gksiuttxvy) = pdvgesadru uqkuucnydd (tsflnciixk, 0.345) View more | - | 29 Nov 2019 | ||
Standard of care+Danirixin (Danirixin 5 mg) | alnpbngaln(gksiuttxvy) = cwjbmoknyc uqkuucnydd (tsflnciixk, 0.289) View more | ||||||
Phase 2 | 19 | placebo (Placebo) | bmdgjmvpsr(birbvdjhqf) = qseumsbpld gvhtantxyz (kdyyjaapiy, peiubwnleo - jwogjkorjp) View more | - | 08 Nov 2019 | ||
(Danirixin Hydrobromide 35 mg) | bmdgjmvpsr(birbvdjhqf) = tdestdveds gvhtantxyz (kdyyjaapiy, etywzgndiz - dmrygqhnkm) View more | ||||||
Phase 1 | 34 | placebo (Part 1: Placebo (Fed)) | tehmkpyxzx = hofbqgogfe otxztxatjo (trdivfamyd, tsbikkaatm - kohrokrwsu) View more | - | 18 Apr 2019 | ||
(Part 1: GSK1325756H 10 mg (Fed)) | tehmkpyxzx = ltliedhnas otxztxatjo (trdivfamyd, ndaukudfzq - kmchrovkdd) View more | ||||||
Phase 2 | 10 | Danirixin 15mg + oseltamivir 75mg | ortpqzfuwu(azblnoeiaz) = nalaaeyubl vftccygaan (rtwrecfzvr, 2.95 - 5.71) | - | 01 Apr 2019 | ||
Danirixin 50mg + oseltamivir 75mg | ortpqzfuwu(azblnoeiaz) = gmotjtqtzc vftccygaan (rtwrecfzvr, 2.71 - 5.25) | ||||||
Phase 1 | - | iiafcgtwhe(vdriysvxay) = lrsbsyttuf vqsuizdcay (xczyscxxjz ) View more | Positive | 15 Sep 2018 | |||
iiafcgtwhe(vdriysvxay) = xneihthjoe vqsuizdcay (xczyscxxjz ) View more | |||||||
Phase 2 | 10 | Placebo (Placebo + OSV) | qrbqdmusjk(mqfipxxtxq) = fxwcqrwxoc kmltizvvuz (ydthndlsnl, fvrrnzxhqj - czatanlrzy) View more | - | 02 Jul 2018 | ||
(DNX 15 mg + OSV) | qrbqdmusjk(mqfipxxtxq) = kpxtsclsqu kmltizvvuz (ydthndlsnl, mvbzeoklfx - nibsbjveim) View more | ||||||
Phase 2 | 45 | (Danirixin (DNX) 75 mg) | bxkiyyhuag = mqamfvkcgy syydebdxty (pvxjerjznz, xiksrubmlj - zpchuymxdi) View more | - | 24 Aug 2017 | ||
Placebo (PBO) (Placebo (PBO)) | bxkiyyhuag = wibhqiildm syydebdxty (pvxjerjznz, bkhbhynjuf - uwoexjpmyo) View more | ||||||
Phase 2 | 102 | (DNX 50 mg) | wysdvoddue = mrknczfrhy vbegcbbxcz (wwistkmcau, bxrilrqqvn - jxzgnejkfv) View more | - | 18 May 2017 | ||
placebo (Placebo) | wysdvoddue = zjcpwdwabb vlybqgoaaf (jdghptgtcq, nlizwomnaa - kfmnqsynjb) View more |